Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 26908336 |
US |
83 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 302 | 26908583 |
US |
17 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 303 | 26908586 |
US |
69 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 304 | 26908826 |
US |
70 | 2 |
Injection site pain, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 305 | 26908998 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 306 | 26909151 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 307 | 26909381 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 308 | 26909404 |
US |
67 | 1 |
Blister, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 309 | 26903711 |
US |
8 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 310 | 26903732 |
US |
55 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 311 | 26903768 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 312 | 26903769 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 313 | 26903772 |
US |
1 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 314 | 26903789 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 315 | 26903832 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 316 | 26903913 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 317 | 26903928 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 318 | 26903961 |
US |
89 | 2 |
Eczema, Rash pruritic, Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, POLYETHYLENE GLYCOL 3350, ESCITALOPRAM OXALATE, ESCITALOPRAM, ERGOCALCIFEROL, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 319 | 26903987 |
US |
75 | 2 |
Emotional disorder, Mood disorder due to a general medical condition, Sleep disorder due to a general medical condition, Pruritus, Incorrect dose administered, Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, Affective disorder, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 320 | 26904012 |
US |
33 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 321 | 26904047 |
US |
62 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 322 | 26904075 |
US |
47 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, LORATADINE, LORATADINE TABLET, MUPIROCIN, MUPIROCIN CALCIUM, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 323 | 26904092 |
US |
54 | 1 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 324 | 26904121 |
US |
70 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 325 | 26904213 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 326 | 26904215 |
US |
49 | 2 |
Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 327 | 26904216 |
US |
65 | 2 |
Scratch, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 328 | 26904224 |
US |
1 | |
Exposure via skin contact, Accidental exposure to product, Incorrect disposal of product, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 329 | 26904267 |
US |
75 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 330 | 26904293 |
US |
53 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Injection site bruising, |
||||
DUPILUMAB, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, FLUTICASONE PROPIONATE, ALBUTEROL SULFATE, BUDESONIDE, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE, |
||||
| 331 | 26904365 |
US |
45 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 332 | 26904385 |
US |
74 | 1 |
Product communication issue, Accidental exposure to product, Exposure via skin contact, |
||||
ETANERCEPT, |
||||
| 333 | 26904431 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 334 | 26902726 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 335 | 26902743 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 336 | 26902778 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 337 | 26902954 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 338 | 26903042 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 339 | 26903053 |
US |
66 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 340 | 26903074 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 341 | 26903079 |
US |
32 | 2 |
Exposure via skin contact, Accidental exposure to product, Injury associated with device, |
||||
DUPILUMAB, |
||||
| 342 | 26903081 |
US |
86 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 343 | 26903088 |
US |
84 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 344 | 26903151 |
US |
38 | 2 |
Injection site vesicles, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, SERTRALINE HYDROCHLORIDE, LEVOTHYROXINE SODIUM, CALCIPOTRIENE, BIOTIN, |
||||
| 345 | 26903174 |
US |
32 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 346 | 26903180 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 347 | 26903184 |
US |
77 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 348 | 26903187 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 349 | 26903198 |
US |
44 | 2 |
Inappropriate schedule of product administration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 350 | 26897578 |
US |
77 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 351 | 26897601 |
US |
88 | 2 |
Accidental exposure to product, Exposure via skin contact, Device use error, |
||||
EVOLOCUMAB, |
||||
| 352 | 26897642 |
US |
2 | |
Exposure via skin contact, Incorrect dose administered, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 353 | 26897735 |
US |
11 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 354 | 26897938 |
US |
67 | 2 |
Burning sensation, Accidental exposure to product, Exposure via skin contact, Device malfunction, Injection site pain, |
||||
DUPILUMAB, |
||||
| 355 | 26897955 |
US |
52 | 1 |
Product dispensing issue, Accidental exposure to product, Exposure via skin contact, Visual impairment, |
||||
INSULIN GLARGINE, |
||||
| 356 | 26897957 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 357 | 26898218 |
US |
88 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 358 | 26898395 |
CA |
73 | |
Haematochezia, Fear of injection, Influenza like illness, Stress, Abdominal pain, Arthralgia, Injection site pain, Exposure via skin contact, Accidental exposure to product, Product administration error, Incorrect dose administered, Intentional dose omission, Overdose, Device malfunction, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB, ERGOCALCIFEROL, ROSUVASTATIN, DEXLANSOPRAZOLE, DENOSUMAB, |
||||
| 359 | 26898482 |
US |
11 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 360 | 26898723 |
US |
14 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 361 | 26898742 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 362 | 26899011 |
US |
74 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 363 | 26899145 |
US |
72 | |
Injection site bruising, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 364 | 26899170 |
US |
56 | 2 |
Headache, Flushing, Erythema, Swelling face, Pruritus, Skin burning sensation, Tachycardia, Chest pain, Emotional distress, Rash, Muscular weakness, Pain in extremity, Chest discomfort, Drug hypersensitivity, Injection site reaction, Sensitive skin, Dermatitis contact, Wound, Exposure via skin contact, Dyspnoea exertional, General physical health deterioration, Fatigue, Dizziness, Peripheral swelling, Accidental exposure to product, Product use issue, Product dose omission issue, Product quality issue, Overdose, Device leakage, |
||||
WATER, AMBRISENTAN, AMBRISENTAN, SOTATERCEPT-CSRK, |
||||
| 365 | 26899230 |
US |
2 | |
Injection site haemorrhage, Wrong technique in product usage process, Exposure via skin contact, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 366 | 26899293 |
US |
76 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 367 | 26899308 |
US |
1 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE ORAL, FEXOFENADINE HCL, MAGNESIUM, |
||||
| 368 | 26899348 |
US |
66 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 369 | 26899351 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 370 | 26899359 |
US |
23 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 371 | 26899702 |
US |
75 | 2 |
Exposure via skin contact, Accidental exposure to product, Product communication issue, Wrong technique in device usage process, Intentional dose omission, |
||||
EVOLOCUMAB, TIRZEPATIDE, |
||||
| 372 | 26899716 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 373 | 26899754 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 374 | 26900053 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 375 | 26900081 |
US |
73 | 1 |
Retinal degeneration, Eye swelling, Eye pain, Skin laceration, Dermatitis atopic, Pain in extremity, Rash macular, Peripheral swelling, Dry skin, Pruritus, Erythema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 376 | 26900096 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
SARILUMAB, |
||||
| 377 | 26900104 |
US |
77 | 2 |
Exposure via skin contact, Product dose omission issue, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, ALBUTEROL SULFATE, ALBUTEROL, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 378 | 26900446 |
US |
40 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 379 | 26900454 |
US |
83 | 1 |
Accidental exposure to product, Exposure via skin contact, Incorrect product administration duration, |
||||
SARILUMAB, |
||||
| 380 | 26900831 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 381 | 26900953 |
US |
45 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 382 | 26900976 |
US |
37 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 383 | 26901015 |
US |
30 | |
Accidental exposure to product, Exposure via skin contact, Device difficult to use, |
||||
ERENUMAB-AOOE, |
||||
| 384 | 26901312 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 385 | 26901409 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 386 | 26902259 |
US |
72 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 387 | 26902261 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 388 | 26902268 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 389 | 26902326 |
US |
2 | |
Product knowledge deficit, Inappropriate schedule of product administration, Exposure via skin contact, Product quality issue, Liquid product physical issue, Product container seal issue, |
||||
NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE, |
||||
| 390 | 26902437 |
US |
61 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 391 | 26902502 |
US |
2 | |
Injection site discharge, Incorrect dose administered by device, Device leakage, Exposure via skin contact, Drug dose omission by device, |
||||
| 392 | 26902508 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 393 | 26902573 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 394 | 26892093 |
US |
26 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 395 | 26892238 |
US |
77 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 396 | 26892240 |
US |
42 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 397 | 26892246 |
US |
23 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 398 | 26892249 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 399 | 26892280 |
US |
47 | 2 |
Cough, Nasal congestion, Paranasal sinus discomfort, Nasopharyngitis, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, AMOXICILLIN, |
||||
| 400 | 26892544 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30